Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

(2014) Allison Ackerman et al.   CANCER

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab

(2013) Jeffrey S. Weber et al.   CANCER

BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma

(2013) D. T. Frederick et al.   CLINICAL CANCER RESEARCH

Vemurafenib reverses immunosuppression by myeloid derived suppressor cells

(2013) Bastian Schilling et al.   INTERNATIONAL JOURNAL OF CANCER

Do BRAF inhibitors select for populations with different disease progression kinetics?

(2013) Paolo Antonio Ascierto et al.   Journal of Translational Medicine

Hepatotoxicity with Combination of Vemurafenib and Ipilimumab

(2013) Antoni Ribas et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use

(2012) Paolo A Ascierto et al.   Journal of Translational Medicine

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

(2012) Kim Margolin et al.   LANCET ONCOLOGY

Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations

(2012) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective BRAFV600E Inhibition Enhances T-Cell Recognition of Melanoma without Affecting Lymphocyte Function

(2010) A. Boni et al.   CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

(2009) Jedd D Wolchok et al.   LANCET ONCOLOGY

Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

(2008) Edward L. Korn et al.   JOURNAL OF CLINICAL ONCOLOGY